Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

The author of a new guidebook on GLP-1s and other experts share their tips for how clinicians can optimize patient success ...

T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...

Childhood obesity continues to be a growing problem in out country. So, should the government regulate food advertising like it did with cigarettes?

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Ozempic is approved by the U.S. Food and Drug Administration to treat Type 2 ... is FDA-approved for weight loss in people with obesity or who are overweight with additional risks for ...